Compare Abbott Laboratories (ABT) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Exxon Mobil Corporation — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Exxon Mobil Corporation trades at $140.6 (market cap $587.30B). The key difference: Exxon Mobil Corporation is far larger — about 3.5× Abbott Laboratories's market cap, and Exxon Mobil Corporation pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| ABT | XOM | |
|---|---|---|
Market Cap | $166.94B | $587.30B |
Sector | Health | Energy |
52-Week High | $136.62 | $171.52 |
52-Week Low | $82.57 | $105.83 |
Enterprise Value | $193.69B | $626.52B |
Dividend Yield | 2.63% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ExxonMobil (XOM) trades at $136.44, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong operational cash flow of $52.0B in 2025 and a healthy balance sheet with 15.44% debt-to-capitalization. Recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $150-160 per barrel amid Middle East tensions.
XOM presents a mixed outlook with attractive valuation metrics (P/E 22.97, below energy sector average) and analyst consensus target of $172.79 (26% upside). However, declining revenue trends ($323.9B in 2025 vs. $398.7B in 2022) and bearish technical indicators suggest near-term headwinds. The stock offers income potential with recent $1.03 dividend but faces oil price volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
